MedPath

Actinogen Medical Expands Alzheimer's Drug Trial to US

Actinogen Medical Limited has initiated a significant phase 2b/3 trial for its Alzheimer's treatment, Xanamem, with the first US participant enrolled. The trial, spanning 25 sites in the US and Australia, aims to assess the drug's effects on cognitive and functional measures in patients, with interim results anticipated in 2025 and final results in 2026.

Actinogen Medical Limited has launched a pivotal phase 2b/3 trial for its Alzheimer’s treatment, Xanamem, marking a significant step forward in the fight against neurological conditions. The trial has now expanded to include the first US participant, with the study being conducted across 25 sites in both the US and Australia. This extensive trial aims to evaluate the efficacy of Xanamem on cognitive and functional measures in patients suffering from Alzheimer's disease. Interim results from the study are expected to be released in 2025, with the final results anticipated in 2026. This expansion underscores Actinogen Medical's commitment to developing innovative treatments for Alzheimer's and other neurological disorders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Actinogen's Xanamem (Emestedastat) Receives WHO Recognition and Advances in Alzheimer's Trials

Actinogen Medical's Xanamem (emestedastat) has been granted a unique nonproprietary name by the World Health Organization, recognizing it as a first-in-class 11β-HSD1 enzyme inhibitor.

Axsome's AXS-05 Shows Promise in Alzheimer's Agitation Trials, NDA Submission Planned for 2025

Axsome Therapeutics' AXS-05 demonstrated a statistically significant delay in agitation relapse in Alzheimer's patients in the ACCORD-2 Phase 3 trial.

Kinoxis Therapeutics Receives $2.5M Grant to Advance KNX100 for Dementia Agitation

Kinoxis Therapeutics secured a $2.5 million grant to support its Phase 2a CARES-X clinical trial of KNX100 for dementia-related agitation.

INmune Bio Completes Enrollment in Phase 2 Alzheimer's Trial Targeting Neuroinflammation

INmune Bio has finalized patient randomization for its Phase 2 trial (AD02) in early Alzheimer's disease, enrolling a total of 208 patients.

Actinogen Medical's Xanamem Shows Promise in Alzheimer's and Depression Treatment

Actinogen Medical has reported positive investor confidence following a successful General Meeting, supporting the ongoing development of Xanamem.

Sinaptica's Neuromodulation Device Shows Promise in Phase II Alzheimer's Trial

Sinaptica Therapeutics' SinaptiStim system significantly slowed Alzheimer's progression in a Phase II trial, meeting primary and key secondary endpoints.

INmune Bio Completes Enrollment for Phase 2 Trial of XPro™ in Early Alzheimer's Disease

INmune Bio has concluded patient enrollment for its Phase 2 AD02 trial, targeting early Alzheimer's Disease (AD) patients with elevated neuroinflammation biomarkers.

Autobahn Therapeutics Initiates Phase 2 Trial of ABX-002 for Major Depressive Disorder

Autobahn Therapeutics has commenced the AMPLIFY Phase 2 trial to evaluate ABX-002 as an adjunctive treatment for major depressive disorder (MDD).

Actinogen XanaMIA ACW0009 Phase 2b Trial for MCI and Mild Alzheimer's Disease

The Actinogen XanaMIA ACW0009 Phase 2b trial is seeking participants aged 50 or older diagnosed with MCI or mild Alzheimer's disease for a 9-month study involving daily oral tablets, with a 50% chance of receiving a placebo.

Actinogen Optimizes XanaMIA Phase 2b Alzheimer's Disease Trial Design

Actinogen Medical Limited has announced optimizations to its XanaMIA Phase 2b trial for mild-to-moderate Alzheimer's disease, reducing costs by AUD 30 million and speeding up initial results. The trial now focuses on a 10 mg dose group, enrolling 220 patients, and includes Australian sites for the first 100 patients. Additionally, the XanaCIDD trial for cognitive impairment associated with depression has expanded to include UK sites, with results expected by mid-2024.

Reference News

[1]
Actinogen Medical Expands Alzheimer's Drug Trial to US
tipranks.com · Dec 9, 2024

Actinogen Medical Limited has initiated a phase 2b/3 trial for Xanamem, targeting Alzheimer’s treatment, with the first ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy